Predictors of relapse in genotype 1 patients treated with PegIFN-alfa2b and ribavirin due to chronic hepatitis C within a large German multicentric observational study
S Mauss, D Hueppe, M Manns, G Teuber, T Dahhan, S Kaiser, U Meyer, T Witthöfft, R Mendel, B Möller, N Dikopoulos, J Brack, G Tossing, M Bilzer, E Zehnter · Zeitschrift für Gastroenterologie · 2008 · Heft 09
Bibliografische Angaben
Zusammenfassung
Aims: Late treatment failure in chronic hepatitis C (CHC), defined as relapse during follow-up after an end-of-treatment response, occurs in up to 30% of patients treated with a standard combination therapy of pegylated IFN-alfa and ribavirin (Caliceti P, Dig Liver Dis 2004; 36, Suppl. 3: 334–339). Thus far, only hcv-genotype, age, dose of ribavirin and duration of infection have been proposed as predictors of relapse. We sought to identify other potential predictors of relapse in genotype-1 patients who received weight-based PegIFN-alfa-2b and ribavirin within a large ongoing German multicentre observational st…
